Trinity Biotech
TRIB
About: Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Employees: 401
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
255% more capital invested
Capital invested by funds: $468K [Q1] → $1.66M (+$1.19M) [Q2]
113.0% more ownership
Funds ownership: 0.23% [Q1] → 113.22% (+113.0%) [Q2]
7% less funds holding
Funds holding: 27 [Q1] → 25 (-2) [Q2]
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Financial journalist opinion
Based on 3 articles about TRIB published over the past 30 days
